#CLDI

Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering Calidi Biotherapeutics (NYSE AMERICAN: CLDI) priced an underwritten public offering of 10,519,631 units at $0.50 per unit, expected to raise approximately $5.2 million gross before fees. Each unit includes common stock (or a pre-funded warrant) and three warrants (6‑month, 12‑month, 5‑year).The company granted a 45‑day overallotment option for up to an additional 1,575,000 shares/warrants per series (aggregate up to 4,725,000 shares). Certain existing warrants for 2,973,585 shares will be amended to a reduced exercise price of $0.50 upon closing. Closing expected on or about March 9, 2026.

1 week ago

#CLDI Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering

www.stocktitan.net/news/CLDI/calidi-biother...

0 0 0 0

Calidi Biotherapeutics Announces Proposed Public Offering Calidi Biotherapeutics (NYSE AMERICAN: CLDI) announced a proposed underwritten public offering of units consisting of common stock and, for certain buyers, pre-funded warrants, with accompanying common warrants. The securities comprising the units will separate immediately upon issuance.The company expects to grant underwriters a 45-day option to purchase up to an additional 15% of the offering. Proceeds are intended for working capital and general corporate purposes. The offering is subject to market and other conditions and may not be completed.

1 week ago

#CLDI Calidi Biotherapeutics Announces Proposed Public Offering

www.stocktitan.net/news/CLDI/calidi-biother...

0 0 0 0

3 months ago

#CLDI Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025

www.stocktitan.net/news/CLDI/calidi-biother...

0 0 0 0

Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights Calidi Biotherapeutics (NYSE: CLDI) reported Q3 2025 results and operational updates on Nov 13, 2025. The company presented preclinical SITC Nov 7 data showing its RedTail platform and lead candidate CLD-401 are protected from immune clearance after systemic dosing and can selectively replicate and express genetic payloads at metastatic tumor sites.Calidi established a new Scientific Advisory Board, expanded RedTail functionality (programmable membranes and additional payloads), and raised $6.9M gross in an underwritten public offering, bringing 2025 total gross proceeds to $23.0M. Q3 net loss was $5.2M (net loss per share $2.21); a non-cash deemed-warrant-dividend charge increased net loss attributable to shareholders to $10.8M. Cash was $10.4M plus $0.2M restricted as of Sept 30, 2025.

4 months ago

#CLDI Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights

www.stocktitan.net/news/CLDI/calidi-biother...

0 0 0 0

4 months ago

#CLDI Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC

www.stocktitan.net/news/CLDI/calidi-biother...

0 0 0 0

Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting Calidi Biotherapeutics (NYSE American: CLDI) will hold an investor event at the 2025 Society of Immunotherapy for Cancer (SITC) Annual Meeting on Friday, November 7, 2025 from 8:30 AM to 9:30 AM in National Harbor Room 15 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.The presentation will focus on the company’s RedTail platform and lead candidate CLD-401, feature members of Calidi’s scientific advisory board and leadership, and will be live streamed at https://vimeo.com/event/5482626/8149f00207.Calidi said it is conducting IND-enabling studies for CLD-401 and anticipates submitting an Investigational New Drug (IND) application by end of 2026; the company is also pursuing strategic partnerships to accelerate development.

4 months ago

#CLDI Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting

www.stocktitan.net/news/CLDI/calidi-biother...

0 0 0 0

Matica Bio, a CDMO Leader in Oncolytic Virus Manufacturing, Partners with Calidi Biotherapeutics to Advance Calidi's Project Toward IND Matica Bio (CDMO) and Calidi Biotherapeutics (CLDI) announced a strategic partnership on Nov 3, 2025 to advance Calidi's lead oncolytic candidate CLD-401 toward an IND filing. Under the agreement, Matica will provide analytical development, process development, and GMP manufacturing to support IND submission for CLD-401, a tumor-tropic oncolytic vaccinia designed for systemic delivery, tumor-restricted replication, immune priming, and high intratumoral expression of an IL-15 superagonist.Matica will leverage its purpose-built GMP facility in College Station, Texas, and prior oncolytic virus program experience to support Calidi's clinical advancement of the RedTail platform candidate.

4 months ago

#CLDI Matica Bio, a CDMO Leader in Oncolytic Virus Manufacturing, Partners with Calidi Biotherapeutics to Advance Calidi's Project Toward IND

www.stocktitan.net/news/CLDI/matica-bio-a-c...

0 0 0 0

Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting Calidi Biotherapeutics (NYSE: CLDI) will present new preclinical data for its lead candidate CLD-401 at the SITC Annual Meeting (Nov 7–9, 2025).CLD-401 is a systemically delivered, tumor-tropic oncolytic virus from the RedTail platform that reportedly homes to metastatic sites, replicates in tumor cells, induces tumor lysis and immune priming, and expresses high levels of IL-15 superagonist in the tumor microenvironment.Calidi is conducting IND-enabling studies and anticipates submitting an IND by end of 2026 while pursuing strategic partnerships to accelerate development.

4 months ago

#CLDI Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting

www.stocktitan.net/news/CLDI/calidi-biother...

0 0 0 0

Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, has announced the pricing of a $6 million underwritten public offering. The offering consists of 1,472,764 common stock units at $2.00 per unit and 1,528,000 pre-funded warrant units at $1.999 per unit.Each common stock unit includes one share and one Series I warrant, while pre-funded warrant units include one pre-funded warrant and one Series I warrant. The Series I warrants have a $2.00 exercise price and a 5-year term. Ladenburg Thalmann & Co. Inc. is acting as the sole book-running manager, with Laidlaw & Company as co-manager. The offering is expected to close around August 21, 2025.

6 months ago

#CLDI Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering

www.stocktitan.net/news/CLDI/calidi-biother...

0 0 0 0

Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company, reported its Q2 2025 financial results and operational highlights. The company presented promising preclinical data for CLD-401 at ASCO, demonstrating enhanced biological efficacy in delivering IL-15 superagonist to metastatic tumors. Additionally, CLD-201 received FDA Fast Track Designation for soft tissue sarcoma treatment.Financially, Calidi raised $4.6 million through a warrant inducement offering, bringing total 2025 gross proceeds to $15.7 million. The company reported a net loss of $5.7 million ($1.99 per share) in Q2 2025, compared to $7.4 million in Q2 2024. Cash position stood at $5.3 million as of June 30, 2025.

7 months ago

#CLDI Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

www.stocktitan.net/news/CLDI/calidi-biother...

0 0 0 0

7 months ago

🚨 FeetrAI Alert: #CLDI is in the spotlight! Trading at $0.5903, it's caught between mixed signals and market caution. With speculative spikes and bearish momentum, a short position could be strategic. Target: $0.55/$0.52, Stop: $0.62. Dive into the action! 📉📈 #Stocks #Trading

0 0 0 0

7 months ago

🚨 FeetrAI Alert: #CLDI is in the spotlight! Trading at $0.5903, it's caught between support at $0.56 and resistance at $0.66. With a neutral RSI of 51.84 and bearish MACD, consider shorting around $0.60. Target $0.56/$0.52, stop loss at $0.63. Stay sharp for news! 📉📈

0 0 0 0

7 months ago

🚨 Exciting times for #CLDI! A 1-for-12 reverse split has stirred volatility. With mixed signals from technicals and low trading volumes, a short position might be the play. Enter at $0.61, target $0.58 & $0.55, stop loss at $0.63. Stay sharp, traders! 📉 #FeetrAI

0 0 0 0

Market Wire News

@marketwirenews.com

7 months ago

NEWS: ( NYSE: #CLDI ) BioMedNewsBreaks - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces 1-for-12 Reverse Stock Split Effective August 5

0 0 0 0

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025 Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease,

7 months ago

#CLDI Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

www.stocktitan.net/news/CLDI/calidi-announc...

0 0 0 0

Revolutionary Cancer Treatment: Calidi CEO Unveils Game-Changing RedTail Platform Data in Exclusive Investor Session Get exclusive insights into Calidi's breakthrough RedTail platform targeting metastatic tumors. CEO shares clinical data and $560B market strategy. Register now.

7 months ago

#CLDI Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on July 24

www.stocktitan.net/news/CLDI/join-calidi-bi...

0 0 0 0

7 months ago

🚀 Exciting times for #CLDI! Bullish vibes are in the air with positive trial results and potential pharma partnerships. Technicals show momentum with an 8-day EMA at $0.5896. Consider a long position at $0.59, targeting $0.65-$0.70. Stop loss at $0.55. 📈 #FeetrAI

0 0 0 0

7 months ago

🚀 Exciting times for #CLDI! Trading at $0.6111, it's showing bullish vibes with strong upward momentum. 📈 With a positive MACD and RSI at 58, there's room to grow! Consider a long position targeting $0.635 & $0.655. Keep an eye on volume for volatility! #FeetrAI #Stocks

0 0 0 0

7 months ago

🚀 Exciting times for #CLDI! Trading at $0.598, it's above the 10-day SMA, signaling bullish momentum. With RSI at 57 and a positive MACD, there's potential for gains. Targeting $0.62 & $0.65, but watch out for low volume and market risks. Stay sharp! #FeetrAI 📈

0 0 0 0

7 months ago

🚀 Exciting times for #CLDI! With strong upward momentum and bullish signals from MACD & RSI, it's a hot pick. Entry at $0.63, aiming for $0.68 & $0.72. But watch out—low volume hints at buying pressure exhaustion. Stay sharp with a stop loss at $0.60! 📈 #StockWatch

0 0 0 0

8 months ago

🚀 Exciting times for #CLDI! With innovative cancer treatments and strong conference buzz, the stock's on a bullish run. Current price: $0.59. Targeting $0.65 & $0.70 with a stop loss at $0.55. Stay sharp, watch those indicators, and ride the wave! 📈 #FeetrAI #Stocks

0 0 0 0

8 months ago

🚀 Exciting times for #CLDI! With a surge in price to $0.725, Calidi Biotherapeutics is riding high on bullish momentum from their innovative cancer treatment news. 📈 Consider entering at $0.72 with targets at $0.80 & $0.85. Watch RSI & volume for pullbacks! #Stocks #Biotech

0 0 0 0

8 months ago

🚀 Exciting times for #CLDI! Calidi Biotherapeutics is making waves in genetic cancer treatment, sparking bullish momentum. With MACD & RSI indicators pointing up, consider a long position at $0.75, targeting $0.85-$0.90. Stay sharp with a stop loss at $0.70. 📈 #FeetrAI

0 0 0 0

8 months ago

🚀 Exciting times for #CLDI! Trading at $0.76, it's gaining momentum with promising cancer treatment results. RSI & MACD show bullish vibes! 📈 Consider entering at $0.75, targeting $0.85 & $0.95. Stay sharp with a stop loss at $0.70. Let's ride the wave! 🌊 #FeetrAI

0 0 0 0

Market Wire News

@marketwirenews.com

8 months ago

Breaking News: ( NYSE: #CLDI ) TinyGemsBreaks - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in NetworkNewsWire Spotlight on Genetic Medicines

0 0 0 0